We are live on !
Find out more
BVF Inc Portfolio holdings
AUM
$3.04B
Turnover
10.42%
1-Year Est. Return
129.63%
This Fund
S&P 500
This Quarter Est. Return
-16.69%
1 Year Est. Return
+129.63%
3 Year Est. Return
+531.24%
5 Year Est. Return
+1,335.11%
10 Year Est. Return
+16,856.28%
AUM
$2.07B
AUM Growth
-$429M
(-17%)
Cap. Flow
+$142M
Cap. Flow % of AUM
Cap. Flow %
6.88%
Top 10 Holdings %
Top 10 Hldgs %
44.14%
Holding
87
New
6
Increased
22
Reduced
12
Closed
8
Avg Time Held
2.2
years
Top 10 Avg Time Held
0.7
years
Top 20 Avg Time Held
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MoonLake Immunotherapeutics
MLTX
|
+$137M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$48.1M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$32.9M |
| 4 |
Repare Therapeutics
RPTX
|
+$28.7M |
| 5 |
Cullinan Therapeutics
CGEM
|
+$24.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$100M |
| 2 |
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$64.9M |
| 3 |
Protagonist Therapeutics
PTGX
|
+$37.2M |
| 4 |
NGM
NGM Biopharmaceuticals
NGM
|
+$14.6M |
| 5 |
Generation Bio
GBIO
|
+$8.15M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
BVF Inc's Q2 2022 Portfolio in Review
As of Q2 2022, BVF Inc held 87 positions worth $2.07B, down 17% from $2.5B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
BVF Inc deployed $142M of net new capital in Q2 2022, opening 6 new positions and adding to 22 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 21,751,284 shares worth $114M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $37.2M trimmed.
- BVF Inc's largest Q2 2022 buy was MoonLake Immunotherapeutics: 21,751,284 shares worth $114M.
- BVF Inc added most to Centessa Pharmaceuticals in Q2 2022, an estimated $32.9M increase.
- BVF Inc's biggest Q2 2022 reduction was Protagonist Therapeutics, cutting an estimated $37.2M.
- BVF Inc fully exited argenx in Q2 2022, selling an estimated $100M.
- BVF Inc's ten largest holdings make up 44% of its $2.07B portfolio in Q2 2022.
- BVF Inc opened 6 new positions and closed 8 in Q2 2022.
- BVF Inc's portfolio value fell 17% quarter-over-quarter to $2.07B.
Based on BVF Inc's 13F filing for Q2 2022, filed 15 Aug 2022.